2013
DOI: 10.4014/jmb.1303.03078
|View full text |Cite
|
Sign up to set email alerts
|

PTP1B Inhibitory Secondary Metabolites from Marine-Derived Fungal Strains Penicillium spp. and Eurotium sp.

Abstract: The selective inhibition of PTP1B has been widely recognized as a potential drug target for the treatment of type 2 diabetes and obesity. In the course of screening for PTP1B inhibitory fungal metabolites, the organic extracts of several fungal species isolated from marine environments were found to exhibit significant inhibitory effects, and the bioassay-guided investigation of these extracts resulted in the isolation of fructigenine A (1), cyclopenol (2), echinulin (3), flavoglaucin (4), and viridicatol (5).… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 37 publications
(17 citation statements)
references
References 39 publications
(40 reference statements)
0
13
0
Order By: Relevance
“…The first improvement is about methods of bioactivity-guided separation and purification of marine secondary metabolites, which combine the discovery of new compounds with bioactivity assays [ 59 ]. These improvements in technology are dependent upon the automation in NMR and mass spectroscopy (MS), which also allow the study of the functions of new compounds extracted from marine organisms’ secondary metabolites [ 60 , 61 , 62 ]. Second, for the discovery of new lead compounds for drug development, empirical cell-based screening for cytotoxicity has evolved to a more mechanistic approach that targets specific molecular lesions though there are still shortcomings [ 63 ].…”
Section: Resultsmentioning
confidence: 99%
“…The first improvement is about methods of bioactivity-guided separation and purification of marine secondary metabolites, which combine the discovery of new compounds with bioactivity assays [ 59 ]. These improvements in technology are dependent upon the automation in NMR and mass spectroscopy (MS), which also allow the study of the functions of new compounds extracted from marine organisms’ secondary metabolites [ 60 , 61 , 62 ]. Second, for the discovery of new lead compounds for drug development, empirical cell-based screening for cytotoxicity has evolved to a more mechanistic approach that targets specific molecular lesions though there are still shortcomings [ 63 ].…”
Section: Resultsmentioning
confidence: 99%
“…bisacetylenic alcohol ( 191 ) [184]; conicasterol E ( 192 ) [185]; 6”-debromohamacanthin A ( 193 ) [186]; dieckol ( 194 ) [187]; fructigenine A ( 195 ) [188]; geoditin A ( 196 ) [189]; gorgosterol ( 197 ) [190]; gracilioether B ( 198 ) [191]; gracilioether K ( 199 ) [192]; herdmanine K ( 200 ) [193]; hyrtioreticulin A ( 201 ) [194]; new Kunitz-type protease inhibitor InHVJ ( 202 ) [195]; jaspamide ( 203 ) [196]; latonduine A ( 204 ) [197]; leucettine L41 ( 205 ) [169]; manzamine A ( 206 ) [198]; nahuoic acid A ( 207 ) [199]; namalide ( 208 ) [200]; ningalins C and D ( 209 , 210 ) [201]; octaphlorethol A ( 114 ) [120]; petrosaspongiolide M ( 211 ) [202]; petrosiol A ( 212 ) [203]; phidianidine A ( 213 ) [204]; Poly-APS ( 214 ) [205]; Pseudoceratina sp. dibromotyrosine ( 215 ) [206]; pseudopterosin A ( 216 ) [207]; sargachromanol G ( 217 ) [208]; S. graminifolium polysaccharide ( 218 ) [209]; S. patens phloroglucinol ( 219 ) [210]; S. xiamenensis benzopyran ( 220 ) [211]; theonellasterol ( 221 ) [212]; toluquinol ( 222 ) [213]; and U. lactuca fatty acid ( 223 ) [214].…”
Section: Marine Compounds With Miscellaneous Mechanisms Of Actionmentioning
confidence: 99%
“…Table 2 reports new drugs and drug derivatives obtained by different marine organisms proposed in anti-obesity treatment [62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94]. …”
Section: Treatment Of Obesitymentioning
confidence: 99%